Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

NCT01804101 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT01804101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01804101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Not applicable
Overall status
Completed
Start date
May 7, 2013
Completion date
January 10, 2017
Enrollment
48 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute biphenotypic leukemia, acute myeloid leukemia, myelodysplastic syndrome, untreated adult acute myeloid leukemia